rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (67 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 7 (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 26.3% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: chemotherapyuncontrolledunstablecardiacperformance status
  Phrases that lowered it: and safetyefficacy andhepatitis virusthe efficacysafety of
• Blinding: double (raises risk) · Design
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• An Investigation of rhTPO With Different Frequencies in the Management of ITP NCT02139501 · started 2014 · scored riskier than 18% of active trials completed
• An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) NCT02153060 · started 2014 · scored riskier than 14% of active trials completed
• rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP NCT01525836 · started 2011 · scored riskier than 20% of active trials completed
• A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy NCT02391272 · started 2015 · scored riskier than 20% of active trials completed
• Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) NCT01506414 · started 2009 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.